Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies

Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer's disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), which metabolizes tryptophan to kynurenine (KYN), rescues hippocampal memory function in mouse preclinical models of AD by restoring astrocyte metabolism. Activation of astrocytic IDO1 by amyloid β and tau oligomers increases KYN and suppresses glycolysis in an aryl hydrocarbon receptor-dependent manner. In amyloid and tau models, IDO1 inhibition improves hippocampal glucose metabolism and rescues hippocampal long-term potentiation in a monocarboxylate transporter-dependent manner. In astrocytic and neuronal cocultures from AD subjects, IDO1 inhibition improved astrocytic production of lactate and uptake by neurons. Thus, IDO1 inhibitors presently developed for cancer might be repurposed for treatment of AD.

Authors

Institutions

Publication Details

Journal
Science
Published
2024-08-22
DOI
https://doi.org/10.1126/science.abm6131
Citations
165
Primary Topic
Tryptophan and brain disorders
Type
article
Field-Weighted Citation Impact
25.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies

Brenita C. Jenkins, Hannah Ennerfelt, Traci Fang Newmeyer, Melanie R. McReynolds et al.
165 citations
Science
Tryptophan and brain disorders
25.81
article

Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies

Brenita C. Jenkins, Hannah Ennerfelt, Traci Fang Newmeyer, Melanie R. McReynolds, Jeffrey R. Jones, Praveena Prasad, Frank M. Longo, Yoo Jin Jung, Aarooran S. Durairaj, Katrin I. Andreasson, Ling Liu, Makoto Suematsu, Edward Norman Wilson, Paras S. Minhas, Matthew Matrongolo, Geidy E. Serrano, Joshua D. Rabinowitz, Erik M. Ullian, Kelly J. Heard, Travis E. Conley, Amira Latif‐Hernandez, Yuki Sugiura, Thomas G. Beach, Fred H. Gage, Takeshi Uenaka, Joshua Crapser, Marius Wernig, Siddhita D. Mhatre, Ryan Goodman, Austin Kang, Qian Wang, Yeonglong Albert Ay, Tao Yang
article en
165 citations

Abstract

Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer's disease (AD), with recent proteomic studies highlighting disrupted glial metabolism in AD. We report that inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), which metabolizes tryptophan to kynurenine (KYN), rescues hippocampal memory function in mouse preclinical models of AD by restoring astrocyte metabolism. Activation of astrocytic IDO1 by amyloid β and tau oligomers increases KYN and suppresses glycolysis in an aryl hydrocarbon receptor-dependent manner. In amyloid and tau models, IDO1 inhibition improves hippocampal glucose metabolism and rescues hippocampal long-term potentiation in a monocarboxylate transporter-dependent manner. In astrocytic and neuronal cocultures from AD subjects, IDO1 inhibition improved astrocytic production of lactate and uptake by neurons. Thus, IDO1 inhibitors presently developed for cancer might be repurposed for treatment of AD.

ScienceVol. 385(6711)
Salk Institute for Biological Studies (US), Pennsylvania State University (US), Meiji University (JP), University of California, San Francisco (US), Neurosciences Institute (US), Princeton University (US), Central Institute for Experimental Animals (JP), Kyoto University (JP), Chan Zuckerberg Initiative (United States) (US), Banner Sun Health Research Institute (US), Stanford University (US)
Howard Hughes Medical Institute, Arizona Department of Health Services, Jean Perkins Foundation, Japan Agency for Medical Research and Development, Fondation pour la Recherche Médicale, Arizona Biomedical Research Commission, University of California, San Diego, Wu Tsai Neurosciences Institute, Stanford University, National Institute on Aging, National Institute of Neurological Disorders and Stroke, Moonshot Research and Development Program
Good health and well-being
Openalex Percentile: Top 0%
Tryptophan and brain disorders
25.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.